Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience.

ABSTRACT:

Objective

To evaluate the landscape of gene alterations and immunohistochemistry (IHC) profiles of patients with ovarian cancer for targeted therapy and investigate the real-world experience of applying precision medicine.

Methods

Patients diagnosed with ovarian cancer between January 2015 and May 2021 at Severance Hospital and who underwent tumor next-generation sequencing (NGS) were reviewed. Data on germline mutation, IHC markers for mismatch repair deficiency (MMRd), programmed death ligand 1 (PD-L1) expression, and human epidermal growth factor receptor 2 (HER2) expression were acquired. The use of matched therapy and its clinical outcomes were evaluated.

Results

Of the 512 patients who underwent tumor NGS, 403 underwent panel-based germline testing. In patients

SUBMITTER: Kim YN 

PROVIDER: S-EPMC10627761 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature